ALK Abello A/S : Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
March 16, 2017 at 08:04 am EDT
Share
Copenhagen, 2017-03-16 12:55 CET (GLOBE NEWSWIRE) --
ALK (ALKB:DC/ OMX: ALK B / AKABY / AKBLF) reports the following transactions, based on the allotments of share options and conditional shares which ALK has granted in accordance with the sign on fee for the new President & CEO Carsten Hellmann adopted at the company's Annual General Meeting on 15 March 2017:
1.
Details of the person discharging managerial responsibility / person closely associated
a)
Name
Carsten Hellmann
2.
Reason for the notification
a)
Position/status
President & CEO
b)
Initial notification/
amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ALK-Abelló A/S
b)
LEI
529900SGCREUZCZ7P020
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument: (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
B shares
DK0060027142
b)
Nature of the transaction
Allotment based on existing programmes from 2014 and 2015 and a new programme
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 1,832,310
6,800 (2014: share options)
DKK 1,039,500
1,125 (2014: conditional shares)
DKK 1,450,296
5,900 (2015: share options)
DKK 1,053,360
1,140 (2015: conditional shares)
DKK 3,924,533
17,068 (new: share options)
d)
Aggregated information
- Aggregated volume
- Price
32,033
DKK 9,299,999 million
e)
Date of the transaction
2017-01-01
f)
Place of the transaction
NASDAQ Copenhagen
ALK-Abelló A/S
For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
ALK-Abelló A/S published this content on 16 March 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 March 2017 12:03:14 UTC.
Original documenthttp://ir.alk.net/releasedetail.cfm?ReleaseID=1017659
Public permalinkhttp://www.publicnow.com/view/2D4DEE3C6D54BD8D5A0A10C3F845CF7C4B35A5CF
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
ALK-ABELLÓ A/S 
